Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Clinical trial NCT04639271 · UNKNOWN
Trial details
- NCT number
- NCT04639271
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-01
- Primary completion
- 2022-01-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.